TEVA-SUMATRIPTAN DF 25 MG
SUMATRIPTAN (SUMATRIPTAN SUCCINATE) : 25 MG · DIN 02286815 · TEVA CANADA LIMITED
Health Canada status: MARKETED
What is TEVA-SUMATRIPTAN DF?
TEVA-SUMATRIPTAN DF 25 MG contains SUMATRIPTAN (SUMATRIPTAN SUCCINATE) : 25 MG. It is listed in the Health Canada Drug Product Database under DIN 02286815, held by TEVA CANADA LIMITED, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 29-Jun-2011. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is TEVA-SUMATRIPTAN DF used for?
Acute treatment of migraine attacks with or without aura. Not for prophylactic therapy or for hemiplegic, basilar, or ophthalmoplegic migraine.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02286815 |
|---|---|
| Brand name | TEVA-SUMATRIPTAN DF |
| Generic / active ingredient | SUMATRIPTAN (SUMATRIPTAN SUCCINATE) : 25 MG |
| Manufacturer | TEVA CANADA LIMITED |
| Strength | 25 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | N02CC01 SUMATRIPTAN |
| AHFS class | 28:32.28 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 29-Jun-2011 |
| Original market date | 2006-10-30 00:00:00 |
How is it administered?
Minimum effective dose 25mg. Optimal 50mg. Max single dose 100mg. If headache returns, repeat after 2 hours. Max 200mg/24 hours. Swallow whole with water.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in the provided text snippet (Section 11 header present but content missing).
How is it supplied?
TEVA-SUMATRIPTAN: Blister packs of 6 and 24. TEVA-SUMATRIPTAN DF: Bottles of 50; Blister packs of 6, 24, and 100.
Contraindications
Hypersensitivity; ischemic cardiac, cerebrovascular, or peripheral vascular syndromes; valvular heart disease; arrhythmias; uncontrolled hypertension; MAOIs (within 2 weeks); severe hepatic impairment.
Warnings and precautions
Risk of myocardial ischemia/infarction; coronary vasospasm; cerebrovascular events (stroke); medication overuse headache; serotonin syndrome; potential for drowsiness.
Is SUMATRIPTAN in shortage in Canada?
A Canadian shortage report is on file for this molecule: Resolved — reported by SANIS HEALTH INC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code N02CC01 SUMATRIPTAN. 32 of 80 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-SUMATRIPTAN | 100 MG | TABLET | APOTEX INC | MARKETED | DIN 02268396 |
| APO-SUMATRIPTAN | 50 MG | TABLET | APOTEX INC | MARKETED | DIN 02268388 |
| IMITREX | 20 MG | SPRAY | GLAXOSMITHKLINE INC | MARKETED | DIN 02230420 |
| IMITREX | 5 MG | SPRAY | GLAXOSMITHKLINE INC | MARKETED | DIN 02230418 |
| IMITREX | 6 MG / 0.5 ML | SOLUTION | GLAXOSMITHKLINE INC | MARKETED | DIN 02212188 |
| IMITREX DF - TAB 100MG | 100 MG | TABLET | GLAXOSMITHKLINE INC | MARKETED | DIN 02212161 |
| JAMP SUMATRIPTAN | 100 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02545365 |
| JAMP SUMATRIPTAN | 25 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02545349 |
| JAMP SUMATRIPTAN | 50 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02545357 |
| JAMP SUMATRIPTAN DF | 100 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02545314 |
Who else supplies SUMATRIPTAN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. SUMATRIPTAN appears in 269 registered pack listings across 14 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.